CD33 and acute myeloid leukemia: ,90,91 An initial CD33-CAR-T cell phase I trial illustrated the challenges of lymphopenia, a common occurrence in AML that can impede autologous CAR-T cell manufacturing and efficacy, with just three of the 10 enrolled patients in one study able to receive the CAR-T product.91